Topics

NICE recommends Pfizer's Vizimpro, rejects AstraZeneca's Tagrisso, in non-small cell lung cancer

04:39 EDT 5 Jul 2019 | Pharmafile

NICE has announced its decision to recommend Pfizer’s Vizimpro (Dacomitinib) in the treatment of non-small-cell lung cancer (NSCLC) – a U-turn on its previous decision to reject the drug for being an ineffective use of NHS resources.

The recommendation, made after the manufacturer agreed to a confidential discount, will make the drug available on the health service specifically in locally advanced or metastatic NSCLC, that has tested positive for the epidermal growth factor receptor (EGFR) mutation.

read more

Original Article: NICE recommends Pfizer's Vizimpro, rejects AstraZeneca's Tagrisso, in non-small cell lung cancer

NEXT ARTICLE

More From BioPortfolio on "NICE recommends Pfizer's Vizimpro, rejects AstraZeneca's Tagrisso, in non-small cell lung cancer"

Quick Search

Relevant Topics

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

Lung Cancer
Lung cancer is the uncontrolled cell growth in tissues of the lung. Originating in the lungs, this growth may invade adjacent tissues and infiltrate beyond the lungs. Lung cancer, the most common cause of cancer-related death in men and women, is respons...